Author(s):
Ranim Alrouhayyah, Svetlana N. Suslina
Email(s):
alrukhaie-r@rudn.ru
DOI:
10.52711/0974-360X.2026.00615 
Address:
Ranim Alrouhayyah1,2, Svetlana N. Suslina1
1Department of General Pharmaceutical and Biomedical Technology, Institute of Medicine, Peoples’ Friendship University of Russia named after Patrice Lumumba (RUDN University), 6 Miklukho-Maklaya street, Moscow, 117198, Russian Federation.
2Department of Analytical and Food Chemistry, Faculty of Pharmacy, Damascus University, Damascus, Syria.
*Corresponding Author
Published In:
Volume - 19,
Issue - 9,
Year - 2026
ABSTRACT:
Trimetazidine dihydrochloride, a piperazine derivative, has long been used as a safe drug for the long-term treatment of chronic ischemic diseases. However, being a metabolic modulator, trimetazidine dihydrochloride has many potential pharmacological effects and can be successfully used in the treatment of various diseases or disorders associated with energy imbalance or metabolic disorders. The aim of this paper is to analyze some of the published studies devoted to the pharmacological effects and mechanisms of action of trimetazidine dihydrochloride, with special attention to the form and dosage in which it was administered, to justify the development of new pharmaceutical dosage forms of this active pharmaceutical substance. The results of the studies reviewed confirm the prospects of using trimetazidine dihydrochloride in the treatment of various diseases other than ischemic ones, and the relevance of its continued existence. Based on this review, it is possible to propose the development of new pharmaceutical dosage forms of trimetazidine dihydrochloride, different from those currently available, or its use in other dosages for the treatment of several metabolic disorders.
Cite this article:
Ranim Alrouhayyah, Svetlana N. Suslina. The Intersection of Pharmaceutical Technology and Pharmacology of Trimetazidine dihydrochloride: A Brief Overview. Research Journal Pharmacy and Technology. 2026;19(9):4409-5. doi: 10.52711/0974-360X.2026.00615
Cite(Electronic):
Ranim Alrouhayyah, Svetlana N. Suslina. The Intersection of Pharmaceutical Technology and Pharmacology of Trimetazidine dihydrochloride: A Brief Overview. Research Journal Pharmacy and Technology. 2026;19(9):4409-5. doi: 10.52711/0974-360X.2026.00615 Available on: https://www.rjptonline.org/AbstractView.aspx?PID=2026-19-9-61
REFERENCES:
1. Hemant KJ, Deepak DD. Development and Validation of Spectrophotometric Method for Determination of Trimetazidine Hydrochloride in Bulk and Tablet Dosage Form. Research J. Pharm. and Tech. 2016; 9(9): 1457-1460. doi: 10.5958/0974-360X.2016.00282.1.
2. Bezuglov E. The Application of Trimetazidine in Healthy Individuals: A Systematic Review. European Review for Medical and Pharmacological Sciences. 2023; 27(14). DOI:10.26355/eurrev_202309_33160.
3. Wu L, Luan Y, Li Y, Wang M, He J, Jin CH, et al. Effects of trimetazidine on ventricular remodeling in coronary artery disease patients with left ventricular hypertrophy: the rationale and design of a randomized controlled trial. BMC Cardiovasc Disord. 2020; 20(273): 7p. https://doi.org/10.1186/s12872-020-01557-3.
4. Van de Bovenkamp AA, Geurkink KTJ, Oosterveer FTP, de Man FS, Kok WEM, Bronzwaer PNA. Trimetazidine in heart failure with preserved ejection fraction: a randomized controlled cross-over trial. ESC Heart Failure. 2023; 10(5). DOI:10.1002/ehf2.14418
5. Shu H, Peng Y, Hang W, Zhou N, Wang DW. Trimetazidine in Heart Failure. Front Pharmacol. 2021; 11: 569132. doi: 10.3389/fphar.2020.569132.
6. Singh D, Oladimeji-Salami J, Akindele A. insights on pharmacological and therapeutic potentials of trimetazidine beyond anti-anginal drug: A comprehensive review. European Journal of Pharmacology. 2024; 985(5): 177062. DOI:10.1016/j.ejphar.2024.177062.
7. Temnikova E.A. Pharmacological treatment of stable angina pectoris: the place of trimetazidine. Eurasian heart Journal. 2022; 4(41): 82–89. https://doi.org/10.38109/2225-1685-2022-4-82-89. (In Russian)
8. Avagimyan AA, Kakturskiy LV. Trimetazidine as a modifier of doxorubicin+cyclophosphamideinduced hyperdyslipidemia. The Siberian Journal of Clinical and Experimental Medicine. 2022; 37(2): 105–111. https://doi.org/10.29001/2073-8552-2022-37-2-105-111. (In Russian)
9. Antsiferova OE, Teleshchenko MP, Tsuverkalova YuM, Pokrovsky MV, Gureev VV, Zatolokina MA, et al. Correction of morphofunctional disorders in experimental preeclampsy by combined use of trimetazidine and purified micronized flavonoid fraction as well as their combinations with methylampsy. Pharmacy and Pharmacology. 2020; 8(5): 304-315. DOI: 10.19163/2307-9266-2020-8-5-304-315 7. (In Russian)
10. Zhang W, You B, Qi D, Qiu L, Ripley-Gonzalez JW, Zheng F, et al. Trimetazidine and Exercise Provide Comparable Improvements to High Fat Diet-Induced Muscle Dysfunction through Enhancement of Mitochondrial Quality Control. Sci. Rep. 2021; 11(1): 19116. doi: 10.1038/s41598-021-98771-6.
11. Abdelaziz H, Elsayed Abdelmageed M, Suddek G. Trimetazidine improves dexamethasone-induced insulin resistance and associated hepatic abnormalities in rats. Life Sciences. 2025; 375(10). DOI:10.1016/j.lfs.2025.123747.
12. Nassiri S, Van de Bovenkamp A, Remmelzwaal Sh, Sorea O, de Man F, Handoko Ml. Effects of trimetazidine on heart failure with reduced ejection fraction and associated clinical outcomes: a systematic review and meta-analysis. Open Heart. 2024; 11(1): e002579. DOI:10.1136/openhrt-2023-002579
13. Kumar MD. Cell based therapy in Amyotrophic Lateral Sclerosis. Research J. Pharm. and Tech. 2015; 8(8): 987-990.
14. Scaricamazza S, Salvatori I, Amadio S, Nesci V, Torcinaro A, Giacovazzo G, et al. Repurposing of Trimetazidine for amyotrophic lateral sclerosis: A study in SOD1G93A mice. British Journal of Pharmacology. 2021; 179 (8): 1732– 1752. https://doi.org/10.1111/bph.15738.
15. Dobrowolny G, Lepore E, Martini M, Barberi L, Nunn A, Scicchitano BM, et al. Metabolic Changes Associated with Muscle Expression of SOD1 G93A. Front Physiol. 2018; 9:831. doi:10.3389/fphys.2018.00831.
16. Chiot A, Zaïdi S, Iltis C, Ribon M, Berriat F, Schiaffino L, et al. Modifying macrophages at the periphery has the capacity to change microglialreactivity and to extend ALS survival. Nature Neuroscience. 2020; 23(11): 1339–1351.doi:10.1038/s41593-020-00718-z
17. Salvatori I, Nesci V, Spalloni A, Marabitti V, Muzzi M, Zenuni H. Trimetazidine Improves Mitochondrial Dysfunction in SOD1 Cellular Models of Amyotrophic Lateral Sclerosis through Autophagy Activation. International Journal of Molecular Sciences (IJMS). 2024; 25(6): 3251. DOI:10.3390/ijms25063251.
18. Ghosh N, Katare R. Molecular mechanism of diabetic cardiomyopathy and modulation of microRNA function by synthetic oligonucleotides. Cardiovascular Diabetology. 2018; 17(43): DOI - 10.1186/s12933-018-0684-1.
19. Anwar A, Ma J, Yin X. Exosomes: a potential biomarker and therapeutic targets in diabetic cardiomyopathy. ExRNA. 2024; 6(3):0015. https://doi.org/10.55092/exrna20240015.
20. Liu Y, Zhang J. Nox2 contributes to cardiac fibrosis in diabetic cardiomyopathy in a transforming growth factor-β dependent manner. Int J Clin Exp Pathol. 2015; 8(9): 10908-10914. eCollection 2015.
21. An Y, Xu Bt, Wan Sh-r, Ma X-M, Long Y, Xu Y, et al. The role of oxidative stress in diabetes mellitus-induced vascular endothelial dysfunction. Cardiovasc Diabetol. 2023; 22(1):237. https://doi.org/10.1186/s12933-023-01965-7. 18.
22. Zhang L, Ding WY, Wang ZH, Tang MX, Wang F, Li Y, et al. Early administration of trimetazidine attenuates diabetic cardiomyopathy in rats by alleviating fibrosis, reducing apoptosis and enhancing autophagy. J Transl Med. 2016; 14 (1): 109. doi: 10.1186/s12967-016-0849-1.
23. Tang SG, Liu XY, Wang SP, Wang HH, Jovanović A, Tan W. Trimetazidine prevents diabetic cardiomyopathy by inhibiting Nox2/TRPC3-induced oxidative stress. J Pharmacol Sci. 2019; 139(4):311-318. doi: 10.1016/j.jphs.2019.01.016.
24. Yusuf M, Nasiruddin M, Sultana N, Badruddeen, Akhtar J, Khan MI, et al. Regulatory Mechanism of Caffeic acid on glucose Metabolism in Diabetes. Research J. Pharm. and Tech. 2019; 12(10):4735-4740. doi: 10.5958/0974-360X.2019.00816.3.
25. Chavaradar AH, Jayshree. A Study to Assess the level of Knowledge regarding Diabetiogenic Ophthalmic Complications among type 2 diabetic patients in selected Hospitals of Chitradurga, Karnataka to Develop and provide self Instruction module (SIM). Asian J. Nursing Education and Research. 2019; 9(3):401-405. doi: 10.5958/2349-2996.2019.00087.9.
26. Mareeswari V, Saranya R, Mahalakshmi R, Preethi E. Prediction of Diabetes Using Data Mining Techniques. Research J. Pharm. and Tech. 2017; 10(4): 1098-1104. doi: 10.5958/0974-360X.2017.00199.8.
27. Gharacholou SM, Li Z, Uy JJ, Eckstein LH, Flock CR, Senger JL, et. al. Characteristics and outcomes of patients with peripheral artery disease undergoing endovascular revascularization: A community hospital perspective. Vascular. 2021; 29(3):372-379. DOI:10.1177/1708538120958858.
28. Criqui MH, Aboyans V. Epidemiology of peripheral artery disease. Circ Res. 2015; 116(9):1509–1526. DOI: 10.1161/CIRCRESAHA.116.303849.
29. Lu Y-H, Cai Y, Zhang Y, Li Z-Y. Digital Subtraction Angiography Contrast Material Transport as a Direct Assessment for Blood Perfusion of Middle Cerebral Artery Stenosis. Frontiers in Physiology. 2021;12.DOI:10.3389/fphys.2021.716173
30. Yang Y, Xu Q, Li T, Shao S. Trimetazidine ameliorates hindlimb ischaemic damage in type 2 diabetic mice. Ann Med. 2021; 53(1):1099-1107. doi: 10.1080/07853890.2021.1925147.
31. Kolik LG, Nadorova AV, Stolyaruk VN, Miroshkina IA, Tsorin IB, Kryzhanovskii SA. Anxiolytic properties of trimetazidine in experimental models of increased anxiety. Bulletin of Experimental Biology and Medicine. 2017; 162 (11):643-646. DOI 10.1007/s10517-017-3677-2.
32. Syunyakov TS, Neznamov GG. Evaluation of the therapeutic efficacy and safety of the selective anxiolytic afobazole in generalized anxiety disorder and adjustment disorders: Results of a multicenter randomized comparative study versus diazepam. Therapeutic Archive. 2016; 88(8):73-86. doi: 10.17116/terarkh201688873-86. (in Russian)
33. Magdy Y, Kamar S, Fansa H, Khedr S, Sedky A. Comparative study: trimetazidine versus olanzapine on cognitive dysfunction and behavioral changes in ketamine-induced psychosis model in mice. Egypt J Neurol Psychiatry Neurosurg. 2025; 61(31). https://doi.org/10.1186/s41983-025-00960-x.
34. Akhmetova М, Nigmatullina R, Mindubaуeva F, Tykezhanova G, Niyazova Y, Lepesbayeva G. Features of the effect of serotonin on the inotropic function of the right ventricular myocardium in the early postnatal period in infant rats with altered serotonin levels during their embryogenesis. Research J. Pharm. and Tech. 2022; 15(1): 122-126. doi: 10.52711/0974-360X.2022.00020
35. Jenkins TA, Nguyen JCD, Polglaze KE, Bertrand PP. Influence of Tryptophan and Serotonin on Mood and Cognition with a Possible Role of the Gut-Brain Axis. Nutrients. 2016; 8(1):56. DOI: 10.3390/nu8010056.
36. Dave PH, Vishnupriya V, R. Gayathri. Herbal Remedies for Anxiety and Depression- A Review. Research J. Pharm. and Tech 2016; 9(8): 1253-1256. doi: 10.5958/0974-360X.2016.00237.7.
37. Zakaria FH, Ismail S, Khadijah NMJ. Cerebrospinal Fluid Serotonin level as Biomarker for Neurotoxicity after 3,4-Methylenedioxymethamphetamine (MDMA). Research J. Pharm. and Tech. 2022; 15(8): 3796-3801. doi: 10.52711/0974-360X.2022.00637
38. Chittaranjan A, Eesha Sh. Serotonin Reuptake Inhibitors and Risk of Abnormal Bleeding. Psychiatric Clinics of North America. 2016; 39(3):DOI:10.1016/j.psc.2016.04.010/
39. Mindubaуeva F, Niyazova Y, Nigmatullina R, Sadykova D, Akhmaltdinova L, Salikhova Y, et al. Membrane serotonin transporter as a Biomarker of Pulmonary arterial hypertension in children with Congenital Heart Defect. Research J. Pharm. and Tech. 2020; 13(5): 2435-2438. doi: 10.5958/0974-360X.2020.00436.9
40. Stuckart I, Siepmann T, Reichmann H, Barlinn K. Selective serotonin reuptake inhibitors in the treatment of post-stroke depression. Psychopharmakotherapie. 2018; 25:9-20.
41. Meiyan L, Wei W, Stone Ch, Zhang L, Tian G, Ding J. Beneficial effects of trimetazidine on expression of serotonin and serotonin transporter in rats with myocardial infarction and depression. Neuropsychiatric Disease and Treatment. 2018; 14: 787-797. DOI: 10.2147/NDT.S157441.
42. Almansour A, Alomar M, Bahader A, Shaynawy H, Alotaibi S, Alshahrani A, et al. An Overview on Clinical Presentation and Diagnostic Approach of Cataract in Primary Healthcare Center. International Journal Of Pharmaceutical Research And Allied Sciences. 2021; 10(4): 52-56.
43. Abbas ACh, Al-Kraity WRH, Abbas ECh. Effect Antioxidant and Serotonin Level in the Sera on Type II Diabetes Mellitus Males Patients and Compare with Control Group. Research J. Pharm. and Tech. 2019; 12(5): 2453-2460. doi: 10.5958/0974-360X.2019.00411.6.
44. Chakraborty A, Nandy S, Saha S, De P. An Insight on α-crystallin Interactions with Various Proteins in Systemic Disorders. Journal of Stress Physiology and Biochemistry. 2023; 3. URL: https://cyberleninka.ru/article/n/an-insight-on-crystallin-interactions-with-various-proteins-in-systemic-disorders (дата обращения: 28.07.2025).
45. Dézsi CA. Trimetazidine in practice: review of the clinical and experimental evidence. Am J Ther. 2016; 23(3): e871. DOI: 10.1097/MJT.0000000000000180.
46. Fang W., Ye Q., Yao Y., Xiu Y., Gu F., Zhu Y. Protective effects of trimetazidine in retarding seleniteinduced lens opacification. Curr Eye Res. 2019; 44(12): 1325-36. DOI: 10.1080/02713683.2019.1633359.
47. Swain R, Nandi S, Sahoo RN, Mohapatra S, Mallick S. Trimetazidine Topical Delivery Prevents Carrageenan Induced Retinal Damage and Glucose Induced Lens Opacification by Decreasing Drop of Protein Level. Research square. 2021; DOI: 10.21203/rs.3.rs-890324/v1.
48. Al-kuraishy H. Trimetazidine and COVID-19-induced acute cardiac injury: a missed key. International Journal of Clinical Pharmacy· 2022; DOI: 10.1007/s11096-022-01408-5.
49. Aghajani A, Khakpourian Z, Bakhthiarzadeh S, Adibipour F, Sadr M, Coleman-Fuller N. Trimetazidine May Potentially Confer Neuroprotective Effects against COVID-19-Induced Neurological Sequelae via Inhibition of Death-Associated Protein Kinase 1 (DAPK1) Signaling Pathways: An Evidenced-Based Hypothesis. Tanaffos. 2023; 22(2):182-186.
50. Knowlton KU. Pathogenesis of SARS-CoV-2 induced cardiac injury from the perspective of the virus. J Mol Cell Cardiol. 2020; 147:12. DOI: 10.1016/j.yjmcc.2020.08.002.